Browse articles from EyeWorld.org related to AMD. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ Study: Specific form of AMD linked to high risk of heart disease
➤ Primary endpoints achieved in study of dry eye therapy
➤ First patient enrolled in study for new pharmacologic presbyopia therapy
➤ Company submits IND for advanced AMD treatment candidate
➤ Acquisition of topical dosing technology
➤ Patent granted for oral drug candidate targeting retinal diseases
➤ Complimentary access to video journal
➤ ASCRS news and events
➤ FDA approves brolucizumab injection for DME
➤ NDA filed for geographic atrophy drug
➤ Study: Dietary supplements can slow AMD progression
➤ First global study evaluates AI for diabetic retinopathy and referral uptake
➤ Plans to begin two Phase 3 trials for investigational thyroid eye disease therapy
➤ ASCRS news and events
➤ FDA approves image and data management/analysis platform
➤ Results from pivotal Phase 3 trial for new Demodex treatment
➤ Trial demonstrates safety, efficacy of mydriasis-reversal drug in pediatric patients
➤ Phase 3 pivotal trial for novel dry eye disease, MGD drug candidate
➤ Phase 3 results for investigational geographic atrophy therapy
➤ New coalition supports sustainability in ophthalmology
➤ ASCRS news and events
➤ Launch of Phase 3 clinical trial for presbyopia drop candidate
➤ Topline results for investigational dry eye therapy
➤ Positive findings for photobiomodulation dry AMD treatment
➤ Enrollment completed for investigational oral diabetic retinopathy therapy
➤ Longer-term data from Phase 3 studies evaluating geographic atrophy therapy released
➤ Orphan drug designation granted to investigational retinitis pigmentosa treatment
➤ ASCRS news and events
➤ Results from pivotal amblyopia trial
➤ Phase 2 clinical program for third-generation keratoconus treatment
➤ Study compares tolerability of standard drop vs. novel drug delivery device
➤ Phase 3 clinical studies for investigational presbyopia drop complete
➤ Orphan drug designation granted for fungal keratitis treatment
➤ Full rights regained for investigational dry AMD therapy
➤ ASCRS news and events
➤ FDA grants IND for Stargardt gene therapy
➤ Phase 2 clinical trial evaluates oral nicotinamide and pyruvate effect on visual function
➤ First ophthalmic formulation of bevacizumab moves toward FDA BLA submission
➤ Positive results for faricimab as an investigational treatment for wet AMD, DME
➤ Eye scans and AI predict risk of heart attack
➤ ASCRS news and events
➤ Study evaluates the potential for AI in cataract surgery
➤ Pre-clinical model for dry AMD
➤ Research finds up to 30% of wet AMD patients could stop injections
➤ Prospective study of a new home-based OCT device begins
➤ ASCRS news and events
➤ FDA approves device to treat MGD
➤ Standalone MIGS device trial begins
➤ Topline results for novel dry eye candidate
➤ Orphan drug designation granted for topical LHON treatment
➤ Positive safety results in Phase 1/2a trial for investigational treatment of wet AMD
➤ Updates on two investigational RNA therapies
➤ ASCRS news and events
➤ Discussion of same-day bilateral cataract surgery ➤ DMEK in complex eyes ➤ Do’s and Don’ts of corneal crosslinking for keratoconus ➤ Reconstruction of the ocular surface ➤ Late-breaking developments in retina ➤ Long-term follow-up with port delivery system of ranibizumab for AMD
➤ Enrollment begins in Phase 3 pilocarpine study for presbyopia
➤ New digital platform enhances connectivity among clinic-to-OR technologies
➤ Positive results from Phase 1 safety study of investigational compound for AMD, DME
➤ Alcon to acquire Ivantis
➤ ASCRS news and events
